1
|
Sanz F, Pognan F, Steger-Hartmann T, Díaz C, Asakura S, Amberg A, Bécourt-Lhote N, Blomberg N, Bosc N, Briggs K, Bringezu F, Brulle-Wohlhueter C, Brunak S, Bueters R, Callegaro G, Capella-Gutierrez S, Centeno E, Corvi J, Cronin MTD, Drew P, Duchateau-Nguyen G, Ecker GF, Escher S, Felix E, Ferreiro M, Frericks M, Furlong LI, Geiger R, George C, Grandits M, Ivanov-Draganov D, Kilgour-Christie J, Kiziloren T, Kors JA, Koyama N, Kreuchwig A, Leach AR, Mayer MA, Monecke P, Muster W, Nakazawa CM, Nicholson G, Parry R, Pastor M, Piñero J, Oberhauser N, Ramírez-Anguita JM, Rodrigo A, Smajic A, Schaefer M, Schieferdecker S, Soininen I, Terricabras E, Trairatphisan P, Turner SC, Valencia A, van de Water B, van der Lei JL, van Mulligen EM, Vock E, Wilkinson D. eTRANSAFE: data science to empower translational safety assessment. Nat Rev Drug Discov 2023; 22:605-606. [PMID: 37316648 DOI: 10.1038/d41573-023-00099-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
|
2
|
Theil D, Kuhle J, Brees D, Tritto E, Pognan F, Frieauff W, Penraat K, Meseck E, Valdez R, Hartmann A. Neurofilament Light Chain: A Translational Safety Biomarker for Drug-Induced Peripheral Neurotoxicity. Toxicol Pathol 2023; 51:135-147. [PMID: 37439009 DOI: 10.1177/01926233231180179] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/14/2023]
Abstract
Branaplam is a splicing modulator previously under development as a therapeutic agent for Spinal Muscular Atrophy Type 1 and Huntington's disease. Branaplam increased the levels of survival motor neuron protein in preclinical studies and was well tolerated in early clinical studies; however, peripheral neurotoxicity was observed in a preclinical safety study in juvenile dogs. The aim of this study was to determine whether serum neurofilament light chain (NfL) concentrations in dogs could serve as a monitoring biomarker for branaplam-induced peripheral neurotoxicity. A 30-week time-course investigative study in dogs treated with vehicle control (negative control), neurotoxic pyridoxine (positive control), or branaplam was conducted to assess neuropathology, nerve morphometry, electrophysiological measurements, gene expression profiles, and correlation to NfL serum concentrations. In branaplam-treated animals, a mild to moderate nerve fiber degeneration was observed in peripheral nerves correlating with increased serum NfL concentrations, but there were no observed signs or changes in electrophysiological parameters. Dogs with pyridoxine-induced peripheral axonal degeneration displayed clinical signs and electrophysiological changes in addition to elevated serum NfL. This study suggests that NfL may be useful as an exploratory biomarker to assist in detecting and monitoring treatment-related peripheral nerve injury, with or without clinical signs, associated with administration of branaplam and other compounds bearing a neurotoxic risk.
Collapse
Affiliation(s)
- Diethilde Theil
- Novartis Pharma AG, Basel, Switzerland
- F. Hoffmann-La Roche AG, Basel, Switzerland
| | | | | | | | | | | | - Kelley Penraat
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
| | - Emily Meseck
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
| | - Reginald Valdez
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
- Amgen, Inc., Cambridge, Massachusetts, USA
| | | |
Collapse
|
3
|
Chichagova V, Dorgau B, de Santis C, Georgiou M, Carter M, Hilgen G, Collin J, Queen R, Chung G, Ajeian J, Moya-Molina M, Kustermann S, Pognan F, Hewitt P, Schmitt M, Sernagor E, Armstrong L, Lako M. Human iPSC-derived retinal organoid model for in vitro toxicity screening. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00355-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Kors J, van Mulligen E, van der Lei J, Pognan F, Steger-Hartmann T. eTRANSAFE's Rosetta stone - a new approach to overcome safety translational hurdles. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00299-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Pognan F, Steger-Hartmann T, Díaz C, Blomberg N, Bringezu F, Briggs K, Callegaro G, Capella-Gutierrez S, Centeno E, Corvi J, Drew P, Drewe WC, Fernández JM, Furlong LI, Guney E, Kors JA, Mayer MA, Pastor M, Piñero J, Ramírez-Anguita JM, Ronzano F, Rowell P, Saüch-Pitarch J, Valencia A, van de Water B, van der Lei J, van Mulligen E, Sanz F. The eTRANSAFE Project on Translational Safety Assessment through Integrative Knowledge Management: Achievements and Perspectives. Pharmaceuticals (Basel) 2021; 14:ph14030237. [PMID: 33800393 PMCID: PMC7999019 DOI: 10.3390/ph14030237] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 02/25/2021] [Accepted: 02/27/2021] [Indexed: 12/19/2022] Open
Abstract
eTRANSAFE is a research project funded within the Innovative Medicines Initiative (IMI), which aims at developing integrated databases and computational tools (the eTRANSAFE ToxHub) that support the translational safety assessment of new drugs by using legacy data provided by the pharmaceutical companies that participate in the project. The project objectives include the development of databases containing preclinical and clinical data, computational systems for translational analysis including tools for data query, analysis and visualization, as well as computational models to explain and predict drug safety events.
Collapse
Affiliation(s)
- François Pognan
- Preclinical Safety/Translational Medicine, Novartis, 4057 Basel, Switzerland;
| | | | - Carlos Díaz
- Synapse Research Managers SL, 28006 Madrid, Spain;
| | | | - Frank Bringezu
- Chemical & Preclinical Safety, Merck Healthcare KGaA, 64293 Darmstadt, Germany;
| | | | - Giulia Callegaro
- Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2300 RA Leiden, The Netherlands; (G.C.); (B.v.d.W.)
| | | | - Emilio Centeno
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
| | - Javier Corvi
- Barcelona Supercomputing Center (BSC), 08034 Barcelona, Spain; (S.C.-G.); (J.C.); (J.M.F.); (A.V.)
| | | | | | - José M. Fernández
- Barcelona Supercomputing Center (BSC), 08034 Barcelona, Spain; (S.C.-G.); (J.C.); (J.M.F.); (A.V.)
| | - Laura I. Furlong
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
- MedBioinformatics Solutions SL, 08018 Barcelona, Spain
| | - Emre Guney
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
| | - Jan A. Kors
- Department of Medical Informatics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; (J.A.K.); (J.v.d.L.); (E.v.M.)
| | - Miguel Angel Mayer
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
| | - Manuel Pastor
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
| | - Janet Piñero
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
| | - Juan Manuel Ramírez-Anguita
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
| | - Francesco Ronzano
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
| | - Philip Rowell
- Lhasa Limited, Leeds LS11 5PS, UK; (K.B.); (W.C.D.); (P.R.)
| | - Josep Saüch-Pitarch
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
| | - Alfonso Valencia
- Barcelona Supercomputing Center (BSC), 08034 Barcelona, Spain; (S.C.-G.); (J.C.); (J.M.F.); (A.V.)
- Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain
| | - Bob van de Water
- Leiden Academic Centre for Drug Research (LACDR), Leiden University, 2300 RA Leiden, The Netherlands; (G.C.); (B.v.d.W.)
| | - Johan van der Lei
- Department of Medical Informatics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; (J.A.K.); (J.v.d.L.); (E.v.M.)
| | - Erik van Mulligen
- Department of Medical Informatics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands; (J.A.K.); (J.v.d.L.); (E.v.M.)
| | - Ferran Sanz
- GRIB, Hospital del Mar Institute of Medical Research (IMIM), DCEXS, Pompeu Fabra University (UPF), 08003 Barcelona, Spain; (E.C.); (L.I.F.); (E.G.); (M.A.M.); (M.P.); (J.P.); (J.M.R.-A.); (F.R.); (J.S.-P.)
- Correspondence:
| |
Collapse
|
6
|
Sanz F, Pognan F, Steger-Hartmann T, Díaz C, Cases M, Pastor M, Marc P, Wichard J, Briggs K, Watson DK, Kleinöder T, Yang C, Amberg A, Beaumont M, Brookes AJ, Brunak S, Cronin MTD, Ecker GF, Escher S, Greene N, Guzmán A, Hersey A, Jacques P, Lammens L, Mestres J, Muster W, Northeved H, Pinches M, Saiz J, Sajot N, Valencia A, van der Lei J, Vermeulen NPE, Vock E, Wolber G, Zamora I. Legacy data sharing to improve drug safety assessment: the eTOX project. Nat Rev Drug Discov 2017; 16:811-812. [PMID: 29026211 DOI: 10.1038/nrd.2017.177] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.
Collapse
Affiliation(s)
- Ferran Sanz
- Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, 08003 Barcelona, Spain
| | - François Pognan
- Novartis Institute for Biomedical Research, Basel, CH-4002, Switzerland
| | | | - Carlos Díaz
- Synapse Research Management Partners, 08007 Barcelona, Spain
| | | | | | - Manuel Pastor
- Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, 08003 Barcelona, Spain
| | - Philippe Marc
- Novartis Institute for Biomedical Research, Basel, CH-4002, Switzerland
| | | | | | | | | | - Chihae Yang
- Molecular Networks GmbH, 90411 Nürnberg, Germany
| | | | - Maria Beaumont
- GlaxoSmithKline Research and Development Ltd, Stevenage SG1 2NY, UK
| | | | - Søren Brunak
- Technical University of Denmark (DTU), 2800 Lyngby, Denmark
| | | | | | - Sylvia Escher
- Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), 30625 Hannover, Germany
| | - Nigel Greene
- Pfizer Ltd, Groton, Connecticut 06340, USA. Current affiliation: AstraZeneca, Waltham, Massachusettts 02451, USA
| | | | - Anne Hersey
- European Bioinformatics Institute, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
| | | | | | | | | | | | - Marc Pinches
- AstraZeneca AB, SK10 2NA Cheshire, UK. Current affiliation: Lhasa Ltd, Leeds LS11 5PS, UK
| | - Javier Saiz
- Universitat Politècnica de València, 46022 València, Spain
| | | | - Alfonso Valencia
- ICREA, 08010 Barcelona, Spain & Barcelona Supercomputing Center (BSC), 08034 Barcelona, Spain
| | - Johan van der Lei
- Erasmus Universitair Medisch Centrum, 3015 CE Rotterdam, The Netherlands
| | | | - Esther Vock
- Boehringer Ingelheim International GmbH, 88379 Biberach an der Riss, Germany
| | | | - Ismael Zamora
- Lead Molecular Design S.L., 08172 Sant Cugat del Vallès, Spain
| |
Collapse
|
7
|
Vicart A, Kinyamu-Akunda J, Whitebread S, Dumotier B, Urban L, Kluwe W, Moggs J, Pognan F, Chibout SD. Learning from approved kinase inhibitors to better inform on the safety risks of specific kinases. Toxicol Lett 2017. [DOI: 10.1016/j.toxlet.2017.07.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Schümann J, Grevot A, Ledieu D, Wolf A, Schubart A, Piaia A, Sutter E, Côté S, Beerli C, Pognan F, Billich A, Moulin P, Walker UJ. Reduced Activity of Sphingosine-1-Phosphate Lyase Induces Podocyte-related Glomerular Proteinuria, Skin Irritation, and Platelet Activation. Toxicol Pathol 2015; 43:694-703. [PMID: 25630683 DOI: 10.1177/0192623314565650] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Sphingosine-1-phosphate (S1P) lyase is considered as a drug target in autoimmune diseases based on the protective effect of reducing activity of the enzyme in animal models of inflammation. Since S1P lyase deficiency in mice causes a severe, lethal phenotype, it was of interest to investigate any pathological alterations associated with only partially reduced activity of S1P lyase as may be encountered upon pharmacological inhibition. Both genetic reduction of S1P lyase activity in mice and inhibition of S1P lyase with a low-molecular-weight compound in rats consistently resulted in podocyte-based kidney toxicity, which is the most severe finding. In addition, skin irritation and platelet activation were observed in both instances. The similarity of the findings in both the genetic model and the pharmacological study supports the value of analyzing inducible partially target-deficient mice for safety assessment. If the findings described in rodents translate to humans, target-related toxicity, particularly podocyte dysfunction, may limit chronic systemic treatment of autoimmune diseases with S1P lyase inhibitors. Furthermore, partial deficiency or inhibition of S1P lyase appears to provide an in vivo rodent model to enable studies on the mechanism of podocyte dysfunction.
Collapse
Affiliation(s)
- Jens Schümann
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Armelle Grevot
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - David Ledieu
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Armin Wolf
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Anna Schubart
- Autoimmunity, Transplantation, and Inflammation, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Alessandro Piaia
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Esther Sutter
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Serge Côté
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Christian Beerli
- Autoimmunity, Transplantation, and Inflammation, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - François Pognan
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Andreas Billich
- Autoimmunity, Transplantation, and Inflammation, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Pierre Moulin
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Ursula Junker Walker
- Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland
| |
Collapse
|
9
|
Balavenkatraman K, Vicart A, Couttet P, Ledieu D, Hopfer U, Rathfelder N, Bertschi B, Greutmann B, Marcellin M, Chibout S, Lambert A, Moggs J, Pognan F, Wolf A. Pharmacodynamic profiling of EGFR inhibitors in human keratinocytes. Toxicol Lett 2013. [DOI: 10.1016/j.toxlet.2013.05.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Riebel V, Brecht K, Bonifacio A, Marcellin M, Couttet P, Chibout S, Pognan F, Wolf A, Uteng M. Arctigenin's mode of toxicity in oxidative metabolizing cell lines. Toxicol Lett 2013. [DOI: 10.1016/j.toxlet.2013.05.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Vacchi-Suzzi C, Bauer Y, Berridge BR, Bongiovanni S, Gerrish K, Hamadeh HK, Letzkus M, Lyon J, Moggs J, Paules RS, Pognan F, Staedtler F, Vidgeon-Hart MP, Grenet O, Couttet P. Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS One 2012; 7:e40395. [PMID: 22859947 PMCID: PMC3409211 DOI: 10.1371/journal.pone.0040395] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2012] [Accepted: 06/06/2012] [Indexed: 11/19/2022] Open
Abstract
Anti-cancer therapy based on anthracyclines (DNA intercalating Topoisomerase II inhibitors) is limited by adverse effects of these compounds on the cardiovascular system, ultimately causing heart failure. Despite extensive investigations into the effects of doxorubicin on the cardiovascular system, the molecular mechanisms of toxicity remain largely unknown. MicroRNAs are endogenously transcribed non-coding 22 nucleotide long RNAs that regulate gene expression by decreasing mRNA stability and translation and play key roles in cardiac physiology and pathologies. Increasing doses of doxorubicin, but not etoposide (a Topoisomerase II inhibitor devoid of cardiovascular toxicity), specifically induced the up-regulation of miR-208b, miR-216b, miR-215, miR-34c and miR-367 in rat hearts. Furthermore, the lowest dosing regime (1 mg/kg/week for 2 weeks) led to a detectable increase of miR-216b in the absence of histopathological findings or alteration of classical cardiac stress biomarkers. In silico microRNA target predictions suggested that a number of doxorubicin-responsive microRNAs may regulate mRNAs involved in cardiac tissue remodeling. In particular miR-34c was able to mediate the DOX-induced changes of Sipa1 mRNA (a mitogen-induced Rap/Ran GTPase activating protein) at the post-transcriptional level and in a seed sequence dependent manner. Our results show that integrated heart tissue microRNA and mRNA profiling can provide valuable early genomic biomarkers of drug-induced cardiac injury as well as novel mechanistic insight into the underlying molecular pathways.
Collapse
Affiliation(s)
- Caterina Vacchi-Suzzi
- Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Yasmina Bauer
- Translational Science Biology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - Brian R. Berridge
- Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America
| | - Sandrine Bongiovanni
- Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Kevin Gerrish
- National Institute of Environmental Health Science, National Institutes of Health, Research Triangle Park, North Carolina, United States of America
| | - Hisham K. Hamadeh
- Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, California, United States of America
| | - Martin Letzkus
- Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Jonathan Lyon
- Investigative Preclinical Toxicology, GlaxoSmithKline, Ware, United Kingdom
| | - Jonathan Moggs
- Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Richard S. Paules
- National Institute of Environmental Health Science, National Institutes of Health, Research Triangle Park, North Carolina, United States of America
| | - François Pognan
- Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Frank Staedtler
- Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | | | - Olivier Grenet
- Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Philippe Couttet
- Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
| |
Collapse
|
12
|
Steger-Hartmann T, Pognan F, Sanz F, Diaz C, Sutter A, Pastor M. In silico prediction of in vivo toxicity - the first steps of the e-Tox consortium. Toxicol Lett 2010. [DOI: 10.1016/j.toxlet.2010.03.838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Abstract
Recent advances in technological approaches for mapping and characterizing the epigenome are generating a wealth of new opportunities for exploring the relationship between epigenetic modifications, human disease and the therapeutic potential of pharmaceutical drugs. While the best examples for xenobiotic-induced epigenetic perturbations come from the field of non-genotoxic carcinogenesis, there is growing evidence for the relevance of epigenetic mechanisms associated with a wide range of disease areas and drug targets. The application of epigenomic profiling technologies to drug safety sciences has great potential for providing novel insights into the molecular basis of long-lasting cellular perturbations including increased susceptibility to disease and/or toxicity, memory of prior immune stimulation and/or drug exposure, and transgenerational effects.
Collapse
Affiliation(s)
- Jennifer Marlowe
- Novartis Pharma AG, Investigative Toxicology, Preclinical Safety, Basel, Switzerland.
| | | | | | | | | |
Collapse
|
14
|
Otieno MA, Bavuso N, Milano J, Foster-Brown L, Bui KH, Li Y, Hudzik T, Wescott D, Louden C, Dyroff M, Pognan F. Mechanistic Investigation of N,N-Diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide–Induced Insulin Depletion in the Rat and RINm5F Cells. Toxicol Sci 2008; 105:221-9. [DOI: 10.1093/toxsci/kfn108] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Pognan F. Toxicogenomics applied to predictive and exploratory toxicology for the safety assessment of new chemical entities: a long road with deep potholes. Prog Drug Res 2007; 64:217, 219-38. [PMID: 17195477 DOI: 10.1007/978-3-7643-7567-6_9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Toxicology is the perturbation of metabolism by external factors such as xenobiotics, environmental factors or drugs. As such, toxicology covers a broad range of fields from studies of the whole organism responses to minute biochemical events. Mechanistic toxicogenomics is an attempt to harness genomic tools to understand the physiological basis for a toxic event based on an analysis of transcriptional, translational or metabolomic profiles. These studies are complicated by non-toxic adaptive responses in transcript, protein or metabolite expression levels that have to be distinguished from those that are proximally related to the toxic event. Substantial progress has been made on the identification of biomarkers and the establishment of screens derived from such toxicogenomics studies. The ultimate goal, of course, is predictive toxicogenomics, which is an attempt to infer the likelihood of occurrence of a toxic event with exposure to a new agent based upon comparative responses with large databases of gene, protein or metabolite expression data. Gene expression databases are currently limited by the fact that measurable toxic phenotypes generally precede or at best coincide with the earliest observable changes in transcriptional profiles. Unfortunately, predictive protein databases have been limited by technical difficulties. Metabonomics-based databases, which would probably have the highest predictive value, are limited in turn by the inability to perform high dose studies in humans. This chapter will conclude by reviewing those elements of toxicogenomics that apply specifically to the development of anti-infectives and the potential for accurately modelling the toxicity of future drugs.
Collapse
Affiliation(s)
- François Pognan
- AstraZeneca Pharmaceuticals, Safety Assessment, Macclesfield, Cheshire, UK.
| |
Collapse
|
16
|
Hopwood J, Summers C, Pognan F, Barrett G, Jones K, Laine R, Kenna G. A novel method for quantification of canalicular transporter inhibition in primary rat hepatocyte sandwich cultures. Toxicology 2006. [DOI: 10.1016/j.tox.2006.05.090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Morelli JK, Buehrle M, Pognan F, Barone LR, Fieles W, Ciaccio PJ. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol Toxicol 2006; 22:15-27. [PMID: 16463016 DOI: 10.1007/s10565-006-0176-z] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2005] [Accepted: 08/23/2005] [Indexed: 11/26/2022]
Abstract
Several cationic amphiphilic drugs cause local or systemic phospholipidosis (PLD) after chronic exposure in preclinical species. PLD is characterized by the accumulation of drug, phospholipid, and concentric lamellar bodies in cellular lysosomes. We have developed a fluorescence-based in vitro screen that is predictive of PLD using the Cellomics ArrayScan high-content screening platform, which captures and analyzes images from 96-well cell culture microtiter plates using multichannel fluorescence microscopy. I-13.35 adherent mouse spleen macrophage cells were cultured with drug and a fluorescently tagged phospholipid, N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE). Drug concentrations were used in a range from 1 to 100 micro mol/L. After 24 h incubations, the cells were fixed with formalin. NBD-PE uptake was quantified in controls and treated cells. Nuclei were identified by Hoechst 33258 staining and dead cells were identified using ethidium homodimer-2 incorporation. Thus, confounding accumulation of NBD-PE due to cytotoxicity that produces false-positive results at high concentrations was eliminated from quantitation by ethidium staining and employing cell gating (dead cell rejection). The assay was found to be both sensitive and selective in that 26 of 28 positive, phospholipidogenic controls and 8 of 8 negative, non-phospholipidogenic controls were correctly called.
Collapse
Affiliation(s)
- J K Morelli
- Safety Assessment US, Astrazeneca Pharmaceuticals, Wilmington, DE 19850, USA.
| | | | | | | | | | | |
Collapse
|
18
|
Coen M, Ruepp SU, Lindon JC, Nicholson JK, Pognan F, Lenz EM, Wilson ID. Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 2004; 35:93-105. [PMID: 15030884 DOI: 10.1016/j.jpba.2003.12.019] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2003] [Revised: 12/15/2003] [Accepted: 12/15/2003] [Indexed: 01/10/2023]
Abstract
Gene chip array (Affymetrix) data from liver tissue and high resolution 1H NMR spectra from intact liver tissue, tissue extracts and plasma have been analyzed to identify biochemical changes arising from hepatotoxicity in mice dosed with acetaminophen. These data sets have been co-interpreted in terms of common metabolic pathways. The principal metabolic changes comprised a decrease in hepatic glucose and glycogen in intact tissue, coupled with an increase in lipid content, with increases in the levels of glucose, pyruvate, acetate and lactate in plasma, and increases in alanine and lactate in the aqueous tissue extracts. Collectively these data provide evidence for an increased rate of hepatic glycolysis. The metabolic observations were consistent with the altered levels of gene expression relating to lipid and energy metabolism in liver which both preceded and were concurrent with the metabolic perturbations. The results show that these two technology platforms together offer a complementary view into cellular responses to toxic processes, providing new insight into the toxic consequences, even for well-studied therapeutic agents such as acetaminophen.
Collapse
Affiliation(s)
- Muireann Coen
- Biological Chemistry, Biomedical Sciences Division, Faculty of Medicine, Imperial College, Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, UK
| | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Pregnant rabbits were serologically diagnosed as having been infected with Encephalitozoon cuniculi. At necropsy at 28 days of gestation, does, placentas and fetuses were found to be infected with E. cuniculi strain type I as evidenced by using the nested-polymerase chain reaction (PCR) technique, thereby confirming vertical transplacental transmission.
Collapse
Affiliation(s)
- P J R Baneux
- Comparative Medicine, Pfizer Global Research and Development, Amboise, France.
| | | |
Collapse
|
20
|
Abstract
Overdose of acetaminophen (APAP) causes severe centrilobular hepatic necrosis in humans and experimental animals. Here, to explore its mechanism, we administered APAP at subtoxic (150 mg/kg ip) and toxic (500 mg/kg ip) doses to overnight fasted mice. Animals were sacrificed at different time points from 15 min to 4 h postinjection. We assessed liver toxicity by plasma ALT activity and by electron microscopy. Using nylon filter arrays and RTQPCR, we performed genomics analysis in liver. We ran proteomics on liver mitochondrial subfractions using the newly developed quantitative fluorescent 2D-DIGE method (Amersham Pharmacia Biotech UK Limited). As soon as 15 min postinjection, centrilobular hepatocyte mitochondria were already slightly enlarged and GSH total content dropped by a third at top dose. GM-CSF mRNA, which is a granulocyte specific gene likely coming from resident Kupffer cells, was also induced to its maximum of 3-fold at both doses. Chaperone proteins Hsp10 and Hsp60 were readily decreased by half in mitochondria at both doses, most likely by leaking into cytoplasm. Although APAP is known as an apoptotic trigger, no apoptosis was observed at any time point. Most of the protein changes in mitochondria were present at 15 min postinjection, thus preceding most of the gene regulations. The decrease of ATP synthase subunits and beta-oxidation pathway proteins indicated a loss of energy production. As the morphology of mitochondria was also affected very early at top dose, we concluded that APAP toxicity was a direct action of its known reactive metabolite NAPQI, rather than a consequence of gene regulation. However, the latter will either worsen the toxicity or lead toward cell recovery depending on the cellular damage level.
Collapse
Affiliation(s)
- Stefan U Ruepp
- AstraZeneca, Alderley Park, Macclesfield SK10 4TG, Cheshire, United Kingdom
| | | | | | | | | |
Collapse
|
21
|
Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001. [PMID: 11680884 DOI: 10.1002/1615-9861(200103)1:3<377::aid-prot377>3.0.co;2-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Fluorescence two-dimensional differential gel electrophoresis (2-D DIGE*) is a new development in protein detection for two-dimensional gels. Using mouse liver homogenates (control and paracetamol (N-acetyl-p-aminophenol, APAP)-treated), we have determined the quantitative variation in the 2-D DIGE process and established statistically valid thresholds for assigning quantitative changes between samples. Thresholds were dependent on normalised spot volume, ranged from approximately 1.2 fold for large volume spots to 3.5 fold for small volume spots and were not markedly affected by the particular cyanine dye combination or by multiple operators carrying out the dye labelling reaction. To minimise the thresholds, substantial user editing was required when using ImageMaster 2D-Elite software. The difference thresholds were applied to the test system and quantitative protein differences were determined using replicate gels of pool samples and single gels from multiple individual animals (control vs treated in each gel). Throughout, the differences revealed with a particular cyanine dye combination were mirrored almost without exception when the dye combination was reversed. Both pool and individual sample analyses provided unique data to the study. The inter-animal response variability in inbred mice was approximately nine times that contributed by the 2-D DIGE process. A number of the most frequently observed protein changes resulting from APAP-treatment were identified by mass spectrometry. Several of these can be rationalised based on available data on the mechanism of APAP hepatotoxicity but others cannot, indicating that proteomics can provide further insights into the biochemical basis of APAP toxicity.
Collapse
Affiliation(s)
- R Tonge
- Proteomics Group, Enabling Science and Technology (Biology), CTL, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 7TG, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001; 1:377-96. [PMID: 11680884 DOI: 10.1002/1615-9861(200103)1:3<377::aid-prot377>3.0.co;2-6] [Citation(s) in RCA: 608] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Fluorescence two-dimensional differential gel electrophoresis (2-D DIGE*) is a new development in protein detection for two-dimensional gels. Using mouse liver homogenates (control and paracetamol (N-acetyl-p-aminophenol, APAP)-treated), we have determined the quantitative variation in the 2-D DIGE process and established statistically valid thresholds for assigning quantitative changes between samples. Thresholds were dependent on normalised spot volume, ranged from approximately 1.2 fold for large volume spots to 3.5 fold for small volume spots and were not markedly affected by the particular cyanine dye combination or by multiple operators carrying out the dye labelling reaction. To minimise the thresholds, substantial user editing was required when using ImageMaster 2D-Elite software. The difference thresholds were applied to the test system and quantitative protein differences were determined using replicate gels of pool samples and single gels from multiple individual animals (control vs treated in each gel). Throughout, the differences revealed with a particular cyanine dye combination were mirrored almost without exception when the dye combination was reversed. Both pool and individual sample analyses provided unique data to the study. The inter-animal response variability in inbred mice was approximately nine times that contributed by the 2-D DIGE process. A number of the most frequently observed protein changes resulting from APAP-treatment were identified by mass spectrometry. Several of these can be rationalised based on available data on the mechanism of APAP hepatotoxicity but others cannot, indicating that proteomics can provide further insights into the biochemical basis of APAP toxicity.
Collapse
Affiliation(s)
- R Tonge
- Proteomics Group, Enabling Science and Technology (Biology), CTL, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 7TG, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
O'Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267:5421-6. [PMID: 10951200 DOI: 10.1046/j.1432-1327.2000.01606.x] [Citation(s) in RCA: 2240] [Impact Index Per Article: 93.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
We show here the identity of Alamar Blue as resazurin. The 'resazurin reduction test' has been used for about 50 years to monitor bacterial and yeast contamination of milk, and also for assessing semen quality. Resazurin (blue and nonfluorescent) is reduced to resorufin (pink and highly fluorescent) which is further reduced to hydroresorufin (uncoloured and nonfluorescent). It is still not known how this reduction occurs, intracellularly via enzyme activity or in the medium as a chemical reaction, although the reduced fluorescent form of Alamar Blue was found in the cytoplasm and of living cells nucleus of dead cells. Recently, the dye has gained popularity as a very simple and versatile way of measuring cell proliferation and cytotoxicity. This dye presents numerous advantages over other cytotoxicity or proliferation tests but we observed several drawbacks to the routine use of Alamar Blue. Tests with several toxicants in different cell lines and rat primary hepatocytes have shown accumulation of the fluorescent product of Alamar Blue in the medium which could lead to an overestimation of cell population. Also, the extensive reduction of Alamar Blue by metabolically active cells led to a final nonfluorescent product, and hence an underestimation of cellular activity.
Collapse
Affiliation(s)
- J O'Brien
- AstraZeneca, Alderley Park, Macclesfield, UK
| | | | | | | |
Collapse
|
24
|
Pognan F, Masson MT, Lagelle F, Charuel C. Establishment of a rat Sertoli cell line that displays the morphological and some of the functional characteristics of the native cell. Cell Biol Toxicol 1997; 13:453-63. [PMID: 9352123 DOI: 10.1023/a:1007475928452] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Primary rat Sertoli cells are widely used as a model for mechanistic and toxicological studies, since they are often the target of toxicants in vivo. However, their isolation from testicular homogenates is tedious and requires the regular use of numerous immature animals. It is therefore of great interest to have available established cell lines that are usable in vitro for unlimited periods and closely similar to native cells. To this end, we have established a line of Wistar rat Sertoli cells (SerW3) by immortalization of fresh primary cells with the T antigens of the Simian virus (SV40). When plated on Matrigel, this cell line presents many of the functional characteristics of Sertoli cells in vivo. In addition, they are sensitive to cisplatin and secrete transferrin, although they do not show a clear response to follicle-stimulating hormone. They also present many morphological similarities, including the presence of tight junctions which mimic the natural epithelial barrier. Like Sertoli cells in vivo, they show extensive phagocytic activity. Finally, they display all the characteristics of immortalized, but not transformed, cells, i.e., topo-inhibition and apoptosis at confluence or under serum deprivation.
Collapse
Affiliation(s)
- F Pognan
- Pfizer Central Research, Drug Safety Evaluation, Amboise, France
| | | | | | | |
Collapse
|
25
|
Peczyńska-Czoch W, Pognan F, Kaczmarek L, Boratyński J. Synthesis and structure-activity relationship of methyl-substituted indolo[2,3-b]quinolines: novel cytotoxic, DNA topoisomerase II inhibitors. J Med Chem 1994; 37:3503-10. [PMID: 7932579 DOI: 10.1021/jm00047a008] [Citation(s) in RCA: 153] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In furtherance of our SAR study on the chemistry and antitumor activity of fused nitrogen heteroaromatic compounds, a series of linear, methyl-substituted derivatives of 5H- and 6H-indolo[2,3-b]quinolines were synthesized according to the modified Graebe-Ullmann reaction. To establish the relationship between the physicochemical and biological activities of indolo[2,3-b]quinolines, their lipophilic properties, cytotoxic and antimicrobial activity, and ability to induce topoisomerase II dependent pSP65 DNA cleavage in vitro were investigated. We found that the antimicrobial and cytotoxic activity of indolo[2,3-b]quinolines was strongly influenced by the position, and the number of methyl substituents and the presence of methyl group at pyridine nitrogen was essential for the cytotoxicity of these compounds. All indolo[2,3-b]quinolines belonging to the 5H series, i.e., bearing a methyl group on the pyridine nitrogen, showed significant activity against procaryotic and eucaryotic organisms. They inhibited the growth of Gram-positive bacteria and pathogenic fungi at MIC range 3 x 10(-2) to 2.5 x 10(-1) mumol/mL, displayed cytotoxicity against KB cells ID50 in the range 2 x 10(-3) to 9 x 10(-3) mumol/mL, and stimulated the formation of calf thymus topoisomerase II mediated DNA cleavage at concentration between 0.4 and 10 microM. None of the indolo[2,3-b]quinolines belonging to the 6H series, i.e., lacking a methyl group on the pyridine nitrogen, was active in analogous tests. Of the investigated compounds, the most active was 2,5,9,11-tetramethyl-5H-indolo[2,3-b]quinoline, a compound bearing the highest number of symmetrically distributed methyl groups. The interaction of indolo[2,3-b]quinolines with DNA was studied by measuring the increase of calf thymus DNA denaturating temperature (Tm). The delta Tm values for the 5H series were found to be about 10 times as high as those for the 6H compounds. Indolo[2,3-b]quinolines with the highest number of methyl groups had the greatest contribution to the increase in the Tm of calf thymus DNA. The values of delta Tm reached 19 degrees C and 1.6 degrees C for the most substituted compounds of both series.
Collapse
Affiliation(s)
- W Peczyńska-Czoch
- Institute of Organic Chemistry, Biochemistry and Biotechnology, Technical University of Wrocław, Poland
| | | | | | | |
Collapse
|
26
|
Pognan F, Saucier JM, Paoletti C, Kaczmarek L, Nantka-Namirski P, Mordarski M, Peczynska-Czoch W. A carboline derivative as a novel mammalian DNA topoisomerase II targeting agent. Biochem Pharmacol 1992; 44:2149-55. [PMID: 1335251 DOI: 10.1016/0006-2952(92)90341-f] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The DNA intercalating, ellipticine analog drug, 5,11-dimethyl-5H-indol[2,3-b]quinoline, is able to stabilize in vitro the topoisomerase II-DNA cleavable complex and to induce DNA breaks in BPV I episome in rat fibroblasts. Cytotoxicity studies with DC3F cells resistant to ellipticine strongly suggest that topoisomerase II is a cellular target involved in the mechanism of cytotoxic action of this carboline derivative.
Collapse
Affiliation(s)
- F Pognan
- Laboratoire de Biochimie-Enzymologie, URA 158 du CNRS, U 140 de l'INSERM, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Topoisomerase II displays higher affinity for supercoiled DNA compared to the same relaxed DNA. Moreover, cruciform structures are formed in topologically constrained DNA. Here we report that, using S1 nuclease experiments on supercoiled DNA, hairpin structures are located close to numerous topoisomerase II cleavage sites on the BPV I genome. Therefore, DNA secondary structure may play a role in the recognition mechanism of DNA by topoisomerase II.
Collapse
Affiliation(s)
- F Pognan
- Laboratoire de Biochimie-Enzymologie, URA 147, Institut Gustave-Roussy, Villejuif, France
| | | |
Collapse
|
28
|
Affiliation(s)
- F Pognan
- Unités de Biochimie-Enzymoplogie, U140 INSERM, URA 147 CNRS Institut Gustave-Roussy, Villejuif, France
| | | |
Collapse
|
29
|
Bloch E, Lavignon M, Bertrand JR, Pognan F, Morvan F, Malvy C, Rayner B, Imbach JL, Paoletti C. Alpha-anomeric DNA: beta-RNA hybrids as new synthetic inhibitors of Escherichia coli RNase H, Drosophila embryo RNase H and M-MLV reverse transcriptase. Gene 1988; 72:349-60. [PMID: 2468572 DOI: 10.1016/0378-1119(88)90162-x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Nuclease-resistant alpha-anomeric DNA:beta-RNA hybrids are inhibitors of Escherichia coli RNase H, and Drosophila embryo RNase H. RNase H activities were measured by polyacrylamide gel electrophoresis, employing a short substrate, (A)12:d[G-G-(T)12-G-G], or by acid-solubility techniques, using a long substrate, poly(A):poly(dT). Strand exchanges which could be responsible for the observed inhibition have been ruled out by S1 nuclease experiments and by using inhibitors which do not allow strand exchange. Our results suggest that RNase H, for which DNA:RNA duplexes are the natural substrates, binds to non-physiological alpha-DNA:RNA hybrids and is consequently inhibited. These hybrids also inhibit the RNA-dependent DNA polymerase activity of M-MLV reverse transcriptase, therefore appearing as potential inhibitors of at least two reverse transcriptase activities. However, the inhibitory effect of these hybrids with respect to M-MLV reverse transcriptase is also observed with the single-stranded alpha-DNA itself. Unexpectedly, polymerase activity is highly stimulated by alpha-oligos, analogous in their sequence to the beta primer used at a concentration unable to generate a detectable synthesis. These results suggest that the inhibition of reverse transcriptase activity with the alpha:beta may occur at different levels.
Collapse
Affiliation(s)
- E Bloch
- UA 147 CNRS, U 140 INSERM, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|